中国医疗前沿
中國醫療前沿
중국의료전연
CHINA HEALTHCARE INNOVATION
2013年
16期
1-2
,共2页
抗病毒治疗%肝炎%乙型%慢性%乙型肝炎病毒%住院患者
抗病毒治療%肝炎%乙型%慢性%乙型肝炎病毒%住院患者
항병독치료%간염%을형%만성%을형간염병독%주원환자
Antiviral therapy%Hepatitis B%Chronic%Hepatitis B virus%Inpatients
目的了解住院慢性乙型肝炎病毒感染患者的抗病毒治疗现状，为指导合理抗病毒治疗和优化抗病毒治疗方案提供依据。方法根据住院病历采集2013年1-6月于我院住院慢性乙型肝炎病毒感染患者抗病毒治疗情况，统计其抗病毒治疗率及其与患者特征间的关系。结果住院慢性乙型肝炎病毒感染患者共447例，符合抗病毒治疗适应证者422例，抗病毒治疗率为84.1%(355例)，在全部治疗方案中恩替卡韦治疗的构成比最高(43.4%)。初治患者和经治患者抗病毒治疗率分别为79.6%和93.0%(P<0.05)，初治患者采用ADV、LAM单药治疗的比例高于经治患者，联合治疗(NA+IFN或NAs)的比例低于经治患者(P<0.05)。患者性别、年龄、病史、家族史及不同诊断之间抗病毒治疗率无显著差异(P>0.05)。结论住院慢性乙型肝炎病毒感染患者抗病毒治疗正在逐渐规范化，但总体抗病毒治疗率仍需进一步提高。
目的瞭解住院慢性乙型肝炎病毒感染患者的抗病毒治療現狀，為指導閤理抗病毒治療和優化抗病毒治療方案提供依據。方法根據住院病歷採集2013年1-6月于我院住院慢性乙型肝炎病毒感染患者抗病毒治療情況，統計其抗病毒治療率及其與患者特徵間的關繫。結果住院慢性乙型肝炎病毒感染患者共447例，符閤抗病毒治療適應證者422例，抗病毒治療率為84.1%(355例)，在全部治療方案中恩替卡韋治療的構成比最高(43.4%)。初治患者和經治患者抗病毒治療率分彆為79.6%和93.0%(P<0.05)，初治患者採用ADV、LAM單藥治療的比例高于經治患者，聯閤治療(NA+IFN或NAs)的比例低于經治患者(P<0.05)。患者性彆、年齡、病史、傢族史及不同診斷之間抗病毒治療率無顯著差異(P>0.05)。結論住院慢性乙型肝炎病毒感染患者抗病毒治療正在逐漸規範化，但總體抗病毒治療率仍需進一步提高。
목적료해주원만성을형간염병독감염환자적항병독치료현상，위지도합리항병독치료화우화항병독치료방안제공의거。방법근거주원병력채집2013년1-6월우아원주원만성을형간염병독감염환자항병독치료정황，통계기항병독치료솔급기여환자특정간적관계。결과주원만성을형간염병독감염환자공447례，부합항병독치료괄응증자422례，항병독치료솔위84.1%(355례)，재전부치료방안중은체잡위치료적구성비최고(43.4%)。초치환자화경치환자항병독치료솔분별위79.6%화93.0%(P<0.05)，초치환자채용ADV、LAM단약치료적비례고우경치환자，연합치료(NA+IFN혹NAs)적비례저우경치환자(P<0.05)。환자성별、년령、병사、가족사급불동진단지간항병독치료솔무현저차이(P>0.05)。결론주원만성을형간염병독감염환자항병독치료정재축점규범화，단총체항병독치료솔잉수진일보제고。
Objective To investigate the current status of antiviral therapy in inpatients chronically infected with hepatitis B virus, and provide evidence for reasonable guidance and optimization of antiviral therapy. Methods According to medical records, to collect the data of antiviral therapy of the inpatients with chronic hepatitis B virus infection in Qingdao Hospital for Infectious Diseases hospitalizied from January to June, 2013, and to analyze the rates of antiviral therapy and the relationships with the characteristics of patients. Results 447 inpatients with chronic hepatitis B virus infection were enrolled, among which 422 cases met the indications for antiviral therapy. The overall rate of antiviral therapy was 84.1%(355 cases). In all the treatment regiments, the proportion of entecavir was the highest(43.4%). The rates of current antiviral therapy in previously untreated patients and treated patients were 79.6 %and 93.0%(P<0.05), respectively. The proportions of monotherapy with adefovir dipivoxil or lamivudine were higher, and combination therapies(nucleos[t]ide analogue plus interferon or combination of nucleos[t]ide analogue) were lower in previously untreated patients than in treated patients(P<0.05). There were no significant difference of antiviral therapy rates between sex and family history or among the durations of disease, age and diagnosis of patients(P>0.05). Conclusion The antiviral therapy of inpatients with chronic hepatitis B virus infection is gradually standardized, but the overall rate of antiviral therapy needs to be further improved.
